Boehringer Ingelheim and Lilly Restructure their Alliance to Emphasis Full Expertise and Investment on Jardiance

Boehringer Ingelheim and Lilly Restructure their Alliance to Emphasis Full Expertise and Investment on Jardiance

Shots:

  • The global companies modernize their alliance as of Jan 01, 2020 to completely focus their expertise and investment on the development and commercialization of Jardiance (empagliflozin) for T2D, HF and CKD  
  • As per the amended agreement, the companies will revise the margin sharing structure for ongoing payments from Jan 01, 2020. Trajenta (linagliptin) and Basaglar (insulin glargine) will remain to be the part of the alliance, with each partner to take exclusive control of its own product i.e, BI to be responsible for Trajenta and Lilly for Basaglar
  • Jardiance (PO, qd) is a highly selective SGLT2 inhibitor and is the first T2D therapy to include risk reduction in CV death data demonstrated in EMPA-REG OUTCOME study

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: Pharmafile